Design, Synthesis, and Pharmacological Evaluation of Novel <i>N</i>-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors
作者:Daniel A. Rodrigues、Guilherme À. Ferreira-Silva、Ana C. S. Ferreira、Renan A. Fernandes、Jolie K. Kwee、Carlos M. R. Sant’Anna、Marisa Ionta、Carlos A. M. Fraga
DOI:10.1021/acs.jmedchem.5b01525
日期:2016.1.28
This manuscript describes a novel class of N-acylhydrazone (NAH) derivatives that act as histone deacetylase (HDAC) 6/8 dual inhibitors and were designed from the structure of trichostatin A (1). Para-substituted phenyl-hydroxamic acids presented a more potent inhibition of HDAC6/8 than their meta analogs. In addition, the effect of compounds (E)-4-((2-(4-(dimethylamino)benzoyl)hydrazono)methyl)-N-hydroxybenzamide
该手稿描述了一类新型的N-酰基hydr(NAH)衍生物,它起着组蛋白脱乙酰基酶(HDAC)6/8双重抑制剂的作用,并且是根据曲古抑菌素A(1)的结构设计的。与它们的间位类似物相比,对位取代的苯基异羟肟酸对HDAC6 / 8的抑制作用更强。另外,化合物(E)-4-((2-(4-(二甲基氨基)苯甲酰基)肼基)甲基)-N-羟基苯甲酰胺(3c)和(E)-4-((2-(4- (二甲基氨基)苯甲酰基)-2-甲基肼基)甲基)-N-羟基苯甲酰胺(3f)关于α-微管蛋白的乙酰化显示出增加的乙酰化水平。这两种化合物也影响细胞迁移,表明它们抑制了HDAC6。对这些化合物具有最强活性的抗增殖活性的分析表明,化合物3c通过caspase 3/7激活诱导了细胞周期阻滞,而3g诱导了细胞凋亡。这些结果表明,HDAC6 / 8作为未来癌症分子疗法的潜在靶标。